SABS
SAB Biotherapeutics Inc
3.00$
-2.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -407.9% | -4,408.6% | -1,155.8% | -2,959.1% | – | -8,083.0% | – | – | – | – | – | – | – | |
| 77.8% | 309.6% | 210.1% | 388.4% | – | 685.0% | – | – | – | – | – | – | – | |
| 50.5% | 176.0% | 65.4% | 228.6% | – | 587.7% | – | – | – | – | – | – | – | |
| -118.0% | -140.1% | -293.7% | 100.1% | – | -1,642.9% | – | – | – | – | – | – | – | |
| 6.7% | 22.2% | 13.7% | 20.0% | – | 48.3% | – | – | – | – | – | – | – | |
| -3.2% | -22.2% | -3,319.9% | 4,263.5% | – | 8,135.1% | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | 210.9% | – | – | – | – | – | – | – | |
| -11.1% | 22,175.3% | -24.0% | -95.9% | – | -38.5% | – | – | – | – | – | – | – | |
| -422.2% | 17,750.4% | -4,502.8% | 1,219.2% | – | -238.2% | – | – | – | – | – | – | – | |
| -414.6% | -4,430.9% | -1,169.5% | -2,979.1% | – | -8,131.3% | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.